このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

自己免疫性多発性内分泌障害カンジダ症外胚葉性ジストロフィー(APECED)関連円形脱毛症患者の発毛に対するルキソリチニブの有効性と安全性を評価する

自己免疫性多発性内分泌障害カンジダ症外胚葉性ジストロフィー(APECED)関連円形脱毛症患者の発毛に対するルキソリチニブの有効性と安全性を評価する第2相非盲検試験

Background:

Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED) is a problem of the immune system. In people with APECED, the immune system makes a mistake and attacks the body. Some people with APECED have a type of hair loss called alopecia areata (AA). No drugs are approved to treat AA.

Objective:

To see if a study drug (ruxolitinib) can help hair regrowth in people with APECED-associated AA and if it can improve other symptoms caused by the immune system s attack to the body.

Eligibility:

People aged 12 to 65 years with APECED and severe AA.

Design:

Participants will be in this study for up to 10 months. They will have 5 in-person visits and 6 televisits, each about 4 weeks apart. One in-person visit may be up to a 10-day stay in the hospital.

The first in-person visit will include screening. Participants will have a physical exam. They will have blood tests. Photographs may be taken of their skin. They will answer questions about their quality of life.

Participants will begin taking the study drug during their hospital stay. They will take the pills by mouth twice a day for 8 months. Researchers may take tissue samples from participants scalp, gums, and lower lip. Participants may provide samples of urine, stool, nail clippings, and saliva. They may have an eye exam and an ultrasound exam of their abdomen.

Some tests may be repeated in subsequent in-person visits.

In telehealth visits, participants will answer questions about how they are feeling. They will describe and send photos of hair regrowth. They will be asked to have blood drawn and the results sent to the researchers.

調査の概要

詳細な説明

Study Description:

This is a phase 2 open-label study to evaluate the efficacy and safety of the Janus-associated kinase (JAK) inhibitor, ruxolitinib, in severe APECED-associated alopecia areata (AA). Following an 8-week observation period to assess baseline disease state, qualifying participants may be admitted for up to 10 days for an inpatient visit to start receiving twice daily dosing of oral ruxolitinib. The dose will be increased at weeks 8 and 16, but may be maintained or reduced if the participant experiences certain adverse events (AEs). The total duration of the ruxolitinib regimen is 8 months. At in-person study visits, participants will be monitored for AEs/reactions and will complete patient-reported outcome (PRO) metrics to track their symptoms and general wellbeing. Participants will also have televisits during the months when there is no in-person visit, for AE assessment and local blood draws for safety labs.

Family members or household contacts of participants will also be enrolled to complete a quality-of-life survey, for comparison with a corresponding patient survey.

Primary Objective:

To evaluate the efficacy of ruxolitinib on hair regrowth in participants with APECED-associated AA.

Secondary Objectives:

  1. To evaluate the safety of ruxolitinib in patients with APECED-associated AA.
  2. To assess additional measures of efficacy related to hair regrowth in response to ruxolitinib treatment.
  3. To investigate the effect of ruxolitinib on PROs related to hair regrowth.
  4. To evaluate the effect of ruxolitinib on histologic and immunologic features of the skin.

Exploratory Objectives:

  1. To investigate the effect of ruxolitinib on improving clinical symptoms and associated laboratory, histologic, and immunologic abnormalities in affected organs and tissues beyond the skin.
  2. To investigate the effect of ruxolitinib on PROs of affected organs and tissues beyond the skin.
  3. To investigate the effect of ruxolitinib on prevention of development of new APECED associated complications during the 32-week treatment period.
  4. To examine the effects of ruxolitinib on ameliorating immunologic readouts of excessive interferon (IFN)- >=/JAK/STAT signaling in peripheral blood and affected organs and tissues beyond the skin.
  5. To determine whether ruxolitinib treatment affects the composition of microbial communities at the mucocutaneous barriers.

Primary Endpoint:

Response defined as a 30 percent improvement from baseline in the Severity of Alopecia Tool (SALT) score at 32 weeks.

Secondary Endpoints:

  1. Incidence of SAEs, AEs requiring study drug discontinuation, and other AEs.
  2. Achievement of 30 percent improvement of SALT score (SALT30) at week 16.
  3. Achievement of 50 percent improvement of SALT score (SALT50) at week 32.
  4. Achievement of SALT score <=20 at week 32.
  5. Time for participants to achieve SALT score <=20.
  6. Time for participants to achieve SALT30 and SALT50.
  7. Percentage of hair regrowth at week 32.
  8. Improvement of Alopecia Areata Symptom Impact Scale (AASIS) score from baseline at week 32.
  9. Improvement of Dermatology Life Quality Index (DLQI) score (adults) from baseline at week 32.
  10. Improvement of Children s Dermatology Life Quality Index (CDLQI) score (pediatrics) from baseline at week 32.
  11. Improvement of Family Dermatology Life Quality Index (FDLQI) score (family members or household contacts) from baseline at week 32.
  12. Improvement of the 36-Item Short Form Survey (SF-36) score (adults) from baseline at week 32.
  13. Improvement of the Pediatric Quality of Life Inventory (PedsQL) score (pediatrics) from baseline at week 32.
  14. PRO for Scalp Hair Assessment Score of 0 or 1 with a >=2-point improvement from baseline among participants with a score of >=3 at baseline at week 32.
  15. Improvement of AA investigator global assessment (IGA) measure from baseline at week 32.
  16. Achievement of clinician-reported outcome (ClinRO) measure for eyebrow (EB) hair loss 0 or 1 with >=2-point improvement from baseline (among participants with ClinRO measure for EB hair loss >=2 at baseline) at week 32.
  17. Achievement of ClinRO measure for eyelash (EL) hair loss 0 or 1 with >=2-point improvement from baseline (among participants with ClinRO measure for EL hair loss 2 at baseline) at week 32.
  18. Change from baseline in Skindex-16 AA symptoms, emotions, and functioning domain scores at week 32.
  19. Change from baseline in histologic and immunologic abnormalities of scalp tissue at week 32.

Exploratory Endpoints:

  1. Change from baseline in histologic or immunologic abnormalities of salivary gland tissue in participants with Sj(SqrRoot)(Delta)gren s-like syndrome at week 32.
  2. Change from baseline in histologic or immunologic abnormalities of oral mucosal tissue at week 32.
  3. Change from baseline in histologic or immunologic abnormalities of gastric tissue in participants with gastritis at week 32.
  4. Change from baseline in histologic or immunologic abnormalities of duodenal tissue in participants with intestinal dysfunction at week 32.
  5. Time to development of next APECED-associated manifestation(s) over the 32-week treatment period.
  6. Number of APECED-associated manifestations developed over the 32-week treatment period.
  7. Development of new APECED-associated manifestation(s) over the 32-week treatment period.
  8. Change from baseline in irritable bowel syndrome (IBS) quality of life (QOL) and small intestinal bacterial overgrowth (SIBO) questionnaire scores in participants with intestinal dysfunction at week 32.
  9. Change from baseline in salivary flow rate in participants with Sj(SqrRoot)(Delta)gren s-like syndrome at week 32.
  10. Change from baseline in corticosteroid dose requirements, adrenocorticotropic hormone, cortisol, electrolyte, and renin levels in participants with adrenal insufficiency at week 32.
  11. Change from baseline in thyroid hormone replacement dose requirements, thyroid-stimulating hormone (TSH), free and total thyroxine, anti-thyroglobulin, and thyroid peroxidase antibody in participants with hypothyroidism at week 32.
  12. Change from baseline in calcium replacement requirements, intact parathyroid hormone, and calcium levels in participants with hypoparathyroidism.
  13. Change from baseline in insulin requirements, hemoglobin A1C (HbA1c), fasting glucose, insulin, c-peptide, urine ketone, and glucose levels in participants with type 1 diabetes at week 32.
  14. Change from baseline in levels of follicle-stimulating hormone, estradiol, Anti-Mullerian hormone, total and free testosterone, and sex hormone binding globulin in participants with hypogonadism at week 32.
  15. Change from baseline in vitamin B12 and intrinsic factor antibody levels in participants with pernicious anemia at week 32.
  16. Change from baseline in Vitiligo Area Scoring Index (VASI) in participants with vitiligo at week 32.
  17. Change from baseline in Ocular Surface Disease Index score (OSDI) in participants with dry eyes at week 32.
  18. Change from baseline measure corneal fluorescein staining (grading scale), tear breakup time (TBUT, in seconds), automated keratography TBUT, and tear meniscus assessments in participants with keratoconjunctivitis at week 32.
  19. Change from baseline grade of conjunctival redness in participants with keratoconjunctivitis at week 32.
  20. Change from baseline in tear production as assessed by Schirmer s test in participants with Sj(SqrRoot)(Delta)gren s-like syndrome at week 32.
  21. Change from baseline in frequency and severity for oral, vaginal, and/or nail candidiasis during the 32-week treatment period.
  22. Change from baseline in spleen volume as measured by ultrasound at week 32.
  23. Change from baseline in nail appearance in participants with nail dystrophy at week 32.
  24. Improvement in ClinRO PRO for nail appearance from baseline at 32 weeks.
  25. Change from baseline in cytokine- and tissue-specific autoantibodies over the 32-week treatment period.
  26. Change from baseline of levels of phosphorylated STAT molecules in peripheral blood mononuclear cells (PBMCs) over the 32-week treatment period.
  27. Change from baseline in serum levels of IFN-Y, CXCL9, CXCL10, and/or other immune-based biomarkers over the 32-week treatment period.
  28. Change from baseline in transcriptional profile in whole blood and tissue biopsies over the 32-week treatment period.
  29. Change from baseline in the oral, vaginal, stool, and/or skin microbiome over the 32-week treatment period.

研究の種類

介入

入学 (推定)

70

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Maryland
      • Bethesda、Maryland、アメリカ、20892
        • 募集
        • National Institutes of Health Clinical Center
        • コンタクト:
          • For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)
          • 電話番号:TTY dial 711 800-411-1222
          • メール:ccopr@nih.gov

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

12年~75年 (子、大人、高齢者)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

説明

  • INCLUSION CRITERIA:

For participants with APECED-associated AA:

  1. Participant must be able to understand and provide informed consent.

  2. Aged >=12 to <=75 years.

  3. Patients with APECED (genetic or clinical diagnosis) and severe AA (defined as having >=50% total scalp loss at screening per the SALT score).

  4. Duration of hair loss greater than 6 months.

  5. No present evidence of hair regrowth.

  6. Is na(SqrRoot) ve or unresponsive to other treatments for AA.

  7. No treatment for alopecia in the past 2 months prior to study enrollment.

  8. Willingness to use valacyclovir prophylaxis for the prevention of herpes viral reactivation.

  9. Vaccinations should be up to date in agreement with current CDC immunization guidelines prior to start of ruxolitinib.

  10. Proficient in written English.

  11. Participants who can get pregnant or impregnate their partner must agree to use at least one highly effective method of contraception when engaging in sexual activities that can result in pregnancy, starting at screening until 12 weeks after the last dose. Highly effective contraceptive measures include:

    1. Stable use of combined (estrogen- and progestogen-containing) hormonal contraception (oral, intravaginal, transdermal) or progestogen-only hormonal contraception (oral, injectable, implantable) starting 1 month prior to screening.
    2. Intrauterine device; intrauterine hormone-releasing system.
    3. Two barrier methods (eg, condom with spermicide, diaphragm with spermicide, or cervical cap and spermicide). Internal and external condoms may not be used together.
    4. Bilateral tubal ligation.

Periodic abstinence (calendar, symptothermal, and post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhea method are not acceptable methods of contraception.

For family members or household contacts:

  1. Aged >=18 years.
  2. Lives with the participant.
  3. Proficient in written English.

EXCLUSION CRITERIA:

For participants with APECED-associated AA:

  1. Known history of hypersensitivity to ruxolitinib or other JAK inhibitors.

  2. History of or active skin disease on the scalp other than AA, such as psoriasis or seborrheic dermatitis.

  3. Diagnosis of AA is in question or the pattern of hair loss is such that quantification of hair loss and assessment of regrowth is difficult, eg, patients with androgenic alopecia.

  4. Treated within the last 2 months with intralesional steroids, systemic steroids, anthralin, squaric acid, diphenylcyclopropenone, tacrolimus, minoxidil, or other medication that, in the opinion of the investigator, may affect hair regrowth.

  5. Current or recent use of any investigational drug (within 3 months or 5 half-lives, whichever is longer, prior to screening).

  6. Scheduled to participate in another clinical study involving an investigational drug during the course of this study.

  7. Use of systemic immunosuppressive or immune-modulating agents within 3 months prior to screening, except systemic steroids 10 mg of prednisone equivalent per day.

  8. Current use of systemic steroids with daily dose >10 mg of prednisone equivalent for any reason or steroid burst for >3 days within 1 month of screening.

  9. History of alcohol or drug abuse within 6 months prior to screening.

  10. Presence of one or more of the following clinically significant laboratory abnormalities:

    1. Serum ALT>=3 times upper limit of normal (ULN).
    2. Serum total bilirubin >=2 times ULN.
    3. ANC<=1000 cells/microliter.
    4. Hemoglobin <=9.0 g/dL.
    5. Platelet count <=100,000/microliter.
    6. Serum creatinine >=2 times ULN.
  11. Planned or anticipated major surgical procedure during the study.

  12. Plans to receive any live vaccines within 1 month of the anticipated first dose of ruxolitinib.

  13. Known or suspected immunodeficiency disorder besides APECED.

  14. History of untreated invasive opportunistic infections (eg, tuberculosis, non-tuberculous mycobacterial infections, histoplasmosis, listeriosis, coccidioidomycosis, pneumocystis pneumonia, aspergillosis) despite infection resolution or otherwise recurrent infections of

    abnormal frequency or prolonged infections suggesting an immune-compromised status as judged by the investigator.

  15. Untreated latent tuberculosis infection.

  16. Infection with HIV.

  17. Untreated infection with hepatitis B or C.

  18. History of serious bacterial infection within the last 3 months prior to screening, unless treated and resolved with antibiotics, or any chronic bacterial infection (eg, chronic pyelonephritis, osteomyelitis).

  19. History of unprovoked DVT, PE, arterial thrombosis, or other thrombotic events.

  20. History of stroke, heart attack, or heart failure.

  21. History of herpes zoster or cytomegalovirus infection that resolved within 2 months prior to screening.

  22. History of basal cell carcinoma, localized squamous cell carcinoma of the skin, or in situ carcinoma of the cervix, unless the participant is in remission and curative therapy was completed at least 12 months prior to screening.

  23. History of other malignancies, unless the participant is in remission and curative therapy was completed at least 5 years prior to screening.

  24. Planned or anticipated use of any prohibited medications and procedures during the study.

  25. Current pregnancy or breastfeeding.

  26. Past or current medical problems or findings from physical examination, EKG, or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant s ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.

There are no exclusion criteria for family members or household contacts.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Ruxolitinib/APECED-AA Patients

All participants receiving IP through this protocol (APECED-AA patients)will receive ruxolitinib.

Ruxolitinib (Jakafi) is approved by the FDA for the treatment of intermediate or high-risk myelofibrosis in adults, polycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyurea, and acute and chronic graft-versus-host disease in adult and pediatric patients (aged =12 years).

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Response defined as a 30% improvement from baseline in the Severity of Alopecia Tool (SALT) score at 32 weeks.
時間枠:32 weeks

To evaluate the efficacy of ruxolitinib on hair regrowth in participants with APECED-associated AA

32 weeks

二次結果の測定

結果測定
メジャーの説明
時間枠
Improvement of AA-IGA measure from baseline at week 32.
時間枠:Week 32

1. To evaluate the safety of ruxolitinib in patients with APECED associated AA 2. Assess additional measures of efficacy related to hair regrowth in response to ruxolitinib treatment. 3. Investigate the effect of ruxolitinib on PROs related to hair regrowth. 4. Evaluate the effect of ruxolitinib on the histologic and immunologic features of the skin.

Week 32
Improvement of DLQI score (adults) from baseline at week 32.
時間枠:Week 32

1. To evaluate the safety of ruxolitinib in patients with APECED associated AA 2. Assess additional measures of efficacy related to hair regrowth in response to ruxolitinib treatment. 3. Investigate the effect of ruxolitinib on PROs related to hair regrowth. 4. Evaluate the effect of ruxolitinib on the histologic and immunologic features of the skin.

Week 32
Improvement of AASIS score from baseline at week 32.
時間枠:Week 32

1. To evaluate the safety of ruxolitinib in patients with APECED associated AA 2. Assess additional measures of efficacy related to hair regrowth in response to ruxolitinib treatment. 3. Investigate the effect of ruxolitinib on PROs related to hair regrowth. 4. Evaluate the effect of ruxolitinib on the histologic and immunologic features of the skin.

Week 32
Percentage of hair regrowth at week 32.
時間枠:Week 32

1. To evaluate the safety of ruxolitinib in patients with APECED associated AA 2. Assess additional measures of efficacy related to hair regrowth in response to ruxolitinib treatment. 3. Investigate the effect of ruxolitinib on PROs related to hair regrowth. 4. Evaluate the effect of ruxolitinib on the histologic and immunologic features of the skin.

Week 32
Time for participants to achieve SALT30 and SALT50.
時間枠:Variable

1. To evaluate the safety of ruxolitinib in patients with APECED associated AA 2. Assess additional measures of efficacy related to hair regrowth in response to ruxolitinib treatment. 3. Investigate the effect of ruxolitinib on PROs related to hair regrowth. 4. Evaluate the effect of ruxolitinib on the histologic and immunologic features of the skin.

Variable
Achievement of SALT50 at week 32.
時間枠:Week 32

1. To evaluate the safety of ruxolitinib in patients with APECED associated AA 2. Assess additional measures of efficacy related to hair regrowth in response to ruxolitinib treatment. 3. Investigate the effect of ruxolitinib on PROs related to hair regrowth. 4. Evaluate the effect of ruxolitinib on the histologic and immunologic features of the skin.

Week 32
Achievement of SALT30 at week 16.
時間枠:Week 16

1. To evaluate the safety of ruxolitinib in patients with APECED associated AA 2. Assess additional measures of efficacy related to hair regrowth in response to ruxolitinib treatment. 3. Investigate the effect of ruxolitinib on PROs related to hair regrowth. 4. Evaluate the effect of ruxolitinib on the histologic and immunologic features of the skin.

Week 16
Change from baseline in histologic and immunologic abnormalities of scalp tissue at week 32.
時間枠:Week 32

1. To evaluate the safety of ruxolitinib in patients with APECED associated AA 2. Assess additional measures of efficacy related to hair regrowth in response to ruxolitinib treatment. 3. Investigate the effect of ruxolitinib on PROs related to hair regrowth. 4. Evaluate the effect of ruxolitinib on the histologic and immunologic features of the skin.

Week 32
Change from baseline in Skindex-16 AA symptoms, emotions, and functioning domain scores at week 32.
時間枠:Week 32

1. To evaluate the safety of ruxolitinib in patients with APECED associated AA 2. Assess additional measures of efficacy related to hair regrowth in response to ruxolitinib treatment. 3. Investigate the effect of ruxolitinib on PROs related to hair regrowth. 4. Evaluate the effect of ruxolitinib on the histologic and immunologic features of the skin.

Week 32
Achievement of ClinRO measure for EL hair loss 0 or 1 with =2-point improvement from baseline (among participants with ClinRO measure for EL hair loss =2 at baseline) at week 32.
時間枠:Week 32

1. To evaluate the safety of ruxolitinib in patients with APECED associated AA 2. Assess additional measures of efficacy related to hair regrowth in response to ruxolitinib treatment. 3. Investigate the effect of ruxolitinib on PROs related to hair regrowth. 4. Evaluate the effect of ruxolitinib on the histologic and immunologic features of the skin.

Week 32
16. Achievement of ClinRO measure for EB hair loss 0 or 1 with =2-point improvement from baseline (among participants with ClinRO measure for EB hair loss =2 at baseline) at week 32.
時間枠:Week 32

1. To evaluate the safety of ruxolitinib in patients with APECED associated AA 2. Assess additional measures of efficacy related to hair regrowth in response to ruxolitinib treatment. 3. Investigate the effect of ruxolitinib on PROs related to hair regrowth. 4. Evaluate the effect of ruxolitinib on the histologic and immunologic features of the skin.

Week 32
PRO for Scalp Hair Assessment Score of 0 or 1 with a =2-point improvement from baseline among participants with a score of =3 at baseline at week 32.
時間枠:Week 32

1. To evaluate the safety of ruxolitinib in patients with APECED associated AA 2. Assess additional measures of efficacy related to hair regrowth in response to ruxolitinib treatment. 3. Investigate the effect of ruxolitinib on PROs related to hair regrowth. 4. Evaluate the effect of ruxolitinib on the histologic and immunologic features of the skin.

Week 32
Improvement of PedsQL score (pediatrics) from baseline at week 32.
時間枠:Week 32

1. To evaluate the safety of ruxolitinib in patients with APECED associated AA 2. Assess additional measures of efficacy related to hair regrowth in response to ruxolitinib treatment. 3. Investigate the effect of ruxolitinib on PROs related to hair regrowth. 4. Evaluate the effect of ruxolitinib on the histologic and immunologic features of the skin.

Week 32
Improvement of SF-36 score (adults) from baseline at week 32.
時間枠:Week 32

1. To evaluate the safety of ruxolitinib in patients with APECED associated AA 2. Assess additional measures of efficacy related to hair regrowth in response to ruxolitinib treatment. 3. Investigate the effect of ruxolitinib on PROs related to hair regrowth. 4. Evaluate the effect of ruxolitinib on the histologic and immunologic features of the skin.

Week 32
Improvement of FDLQI score (family members or household contacts) from baseline at week 32.
時間枠:Week 32

1. To evaluate the safety of ruxolitinib in patients with APECED associated AA 2. Assess additional measures of efficacy related to hair regrowth in response to ruxolitinib treatment. 3. Investigate the effect of ruxolitinib on PROs related to hair regrowth. 4. Evaluate the effect of ruxolitinib on the histologic and immunologic features of the skin.

Week 32
Improvement of CDLQI score (pediatrics) from baseline at week 32.
時間枠:Week 32

1. To evaluate the safety of ruxolitinib in patients with APECED associated AA 2. Assess additional measures of efficacy related to hair regrowth in response to ruxolitinib treatment. 3. Investigate the effect of ruxolitinib on PROs related to hair regrowth. 4. Evaluate the effect of ruxolitinib on the histologic and immunologic features of the skin.

Week 32
Incidence of SAEs, AEs requiring study drug discontinuation, and other AEs.
時間枠:End of Study

1. To evaluate the safety of ruxolitinib in patients with APECED associated AA 2. Assess additional measures of efficacy related to hair regrowth in response to ruxolitinib treatment. 3. Investigate the effect of ruxolitinib on PROs related to hair regrowth. 4. Evaluate the effect of ruxolitinib on the histologic and immunologic features of the skin.

End of Study

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Michail S Lionakis, M.D.、National Institute of Allergy and Infectious Diseases (NIAID)

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2023年1月18日

一次修了 (推定)

2027年12月1日

研究の完了 (推定)

2027年12月1日

試験登録日

最初に提出

2022年5月26日

QC基準を満たした最初の提出物

2022年5月31日

最初の投稿 (実際)

2022年6月1日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月6日

QC基準を満たした最後の更新が送信されました

2026年11月5日

最終確認日

2026年10月30日

詳しくは

本研究に関する用語

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する